How Was Tamoxifen Discovered?

Tamoxifen is one of the most commonly prescribed drugs for breast cancer treatment in the UK, used primarily to reduce the risk of the disease returning. Interestingly, this medication was initially researched for other purposes. Its journey from laboratory compound to life-saving breast cancer drug is a story of unexpected discoveries and near misses.

Origins as a Contraceptive

Research into tamoxifen began in the 1960s, when scientists at the pharmaceutical company ICI were investigating compounds that could work as a morning-after contraceptive pill. The drug works by blocking oestrogen receptors, and researchers believed this property could prevent pregnancy.

Arthur Walpole and his colleagues at ICI developed the compound and pursued patent protection, though the path to approval was far from straightforward.

Tamoxifen never made it to market as a contraceptive. It was explored as a fertility treatment as part of broader studies, but its original intended purpose was quietly abandoned.

The Connection to Breast Cancer

Scientists at the time already understood that oestrogen played a role in some breast cancers. However, this was not a research priority, and the potential for tamoxifen to treat breast cancer was not immediately pursued.

The compound risked being overlooked entirely. That it survived at all was largely due to the persistence of Arthur Walpole, who continued to champion its development when others had lost interest. His enthusiasm kept the research alive during periods when the company saw little commercial value in continuing.

This persistence would eventually prove worthwhile. Throughout the late 1960s and into the 1970s, researchers gradually accumulated evidence suggesting the compound could have applications beyond its original purpose.

Your situation may be slightly different. ask a question below ↓ and our editorial team will reply with our advice.

Clinical Trials and Near Cancellation

A clinical study in 1971 provided the first real evidence that tamoxifen could benefit women with advanced breast cancer. The results showed significant improvements in patients who had few other treatment options available to them.

Despite these promising findings, ICI came close to stopping all further development of tamoxifen in 1972. Walpole's advocacy contributed to its continued development for late stage breast cancer, and the company ultimately decided to bring the drug to market.

Had the development been cancelled at that point, one of the most effective breast cancer treatments available today might never have reached patients.

Tamoxifen Today

Tamoxifen is now a standard treatment option for oestrogen receptor positive breast cancer. It is typically prescribed for five to ten years following initial treatment, depending on individual circumstances. The drug is available on the NHS and is recommended by the National Institute for Health and Care Excellence as part of breast cancer treatment protocols.

The story of tamoxifen's development serves as a reminder that medical breakthroughs do not always follow a predictable path. A compound developed for one purpose can sometimes prove far more valuable for another.

For women currently taking tamoxifen or considering treatment options, your oncologist or breast care nurse can provide guidance on how the drug may fit into your treatment plan. Cancer Research UK and Breast Cancer Now also offer reliable information about tamoxifen and other breast cancer treatments.

If you have questions about side effects or how long you may need to take the medication, speak with your specialist healthcare team. Treatment plans will vary depending on the type and stage of cancer, as well as other individual factors.